Neurotech Pharmaceuticals, Inc., a private biotech company focused on developing transformative therapies for chronic eye diseases, announced the appointment of Beth Marsh as Chief Commercial Officer, effective April 28, 2025. In this role, Beth will lead the commercial organization, including preparing for the U.S. launch of ENCELTO (revakinagene taroretcel-lwey), the first and only approved treatment for adults with idiopathic Macular Telangiectasia Type 2 (MacTel).
Health Technology Insights: Thomas Priselac, Jim Blazar Join K Health AI Consortium
Neurotech Appoints Beth Marsh as Chief Commercial Officer
Beth is an established commercial and strategic business executive with more than two decades of leadership experience and expertise in ophthalmology and retina.
“We are delighted to welcome Beth to Neurotech during this important time as we prepare for the availability of ENCELTO to patients this June,” said Richard Small, Chief Executive Offer. “I am confident that Beth’s expertise in launching new therapies that address unmet needs, and her extensive network and leadership in the retina community will help us quickly scale up our commercial efforts for a successful launch.”
“This is an important and transformative time to join Neurotech as the company prepares for commercialization of the first and only approved treatment for adults suffering with MacTel,” said Beth. “Neurotech has a strong commercial organization and infrastructure in place, and I look forward to partnering with a talented team to achieve the successful launch of ENCELTO. It is an honor to join an organization focused on developing transformative therapies for chronic eye diseases.”
Health Technology Insights: Alithya, OSU Medical Center Go Live with Oracle Scheduling
Beth joins Neurotech from Apellis Pharmaceuticals, where she served as Vice President, North America Sales and Marketing in Ophthalmology, leading the commercial U.S. launch for SYFOVRE, the first approved treatment for geographic atrophy secondary to age-related macular degeneration. Previously, she served in commercial leadership roles at Shire / Takeda Pharmaceuticals as Global Product Strategy Lead, Ophthalmology accountable for the comprehensive commercial strategy and launch readiness for two development-stage ophthalmic programs. Beth’s earlier experience included commercial and business development leadership roles at Aciex Therapeutics, Johnson & Johnson Vision Care, and Santen. She also volunteers as a non-profit leader and past president of OWL: Advancing diversity in leadership in ophthalmology. Beth earned a B.S. in Business Administration in Marketing from Miami University.
About Macular Telangiectasia Type 2 (MacTel)
Macular Telangiectasia Type 2 (MacTel), or idiopathic macular telangiectasia type 2, is a bilateral, neurodegenerative disease in adults with characteristic localized retinal degeneration that cause the gradual loss of cells in the retina, resulting in vision loss and secondary alterations of the retinal vasculature, the network of blood vessels that supplies oxygen and nutrients to the retina.
Health Technology Insights: Biostate AI and Accelerated Cure Project Partner to Develop AI Models for Multiple Sclerosis
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
Source – businesswire
